Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes

CM de Fiebre, EM Meyer, JC Henry, SI Muraskin, WR Kem and RL Papke

Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville 32610-0267.

Investigation of the naturally occurring, nicotinic agonist anabaseine and novel derivatives has shown that these compounds have cytoprotective and memory-enhancing effects. The hypothesis that these arise at least in part through actions on brain nicotinic receptors was evaluated by examining the ability of these compounds to displace the binding of nicotinic ligands and to affect the function of the alpha 4 beta 2 and alpha 7 receptor subtypes expressed in Xenopus oocytes. The derivative 3-(4)-dimethylaminocinnamylidine anabaseine (DMAC) was found to be a selective alpha 7 receptor agonist; it was more potent than nicotine, acetylcholine, anabaseine, and other derivatives at activating the alpha 7 receptor subtype, while displaying little agonist activity at alpha 4 beta 2 and other receptor subtypes. Compared with anabaseine and the other derivatives, DMAC was the most potent at displacing 125I-alpha-bungarotoxin binding (putative alpha 7) and the least potent at displacing [3H]cytisine binding (putative alpha 4 beta 2) to brain membranes. Independently of agonist activities, all of the novel compounds displayed secondary inhibitory activity at both receptor subtypes. At the alpha 4 beta 2 receptor subtype, inhibition by the 3-(2,4)-dimethoxybenzylidene derivative was enhanced by coapplication of acetylcholine, suggesting a noncompetitive form of inhibition. Anabaseine and nicotine prolonged the time course of activation of alpha 4 beta 2 receptors, compared with acetylcholine, suggesting sequential channel-blocking activity. As selective agonists, anabaseine derivatives such as DMAC may be useful for elucidating the function of alpha 7 nicotinic receptors, including their potential role(s) in the cytoprotective and memory-enhancing effects of nicotinic agents.

Volume 47, Issue 1, pp. 164-171, 01/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				N. A. Horenstein, F. M. Leonik, and R. L. Papke Multiple Pharmacophores for the Selective Activation of Nicotinic {alpha}7-Type Acetylcholine Receptors Mol. Pharmacol., December 1, 2008; 74(6): 1496 - 1511. [Abstract] [Full Text] [PDF]

				R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1120 - 1130. [Abstract] [Full Text] [PDF]

				J. Halvard Gronlien, M. Hakerud, H. Ween, K. Thorin-Hagene, C. A. Briggs, M. Gopalakrishnan, and J. Malysz Distinct Profiles of {alpha}7 nAChR Positive Allosteric Modulation Revealed by Structurally Diverse Chemotypes Mol. Pharmacol., September 1, 2007; 72(3): 715 - 724. [Abstract] [Full Text] [PDF]

				A. Olincy, J. G. Harris, L. L. Johnson, V. Pender, S. Kongs, D. Allensworth, J. Ellis, G. O. Zerbe, S. Leonard, K. E. Stevens, et al. Proof-of-Concept Trial of an {alpha}7 Nicotinic Agonist in Schizophrenia. Arch Gen Psychiatry, June 1, 2006; 63(6): 630 - 638. [Abstract] [Full Text] [PDF]

				R. Zhang, N. A. White, F. S. Soti, W. R. Kem, and T. K. Machu N-Terminal Domains in Mouse and Human 5-Hydroxytryptamine3A Receptors Confer Partial Agonist and Antagonist Properties to Benzylidene Analogs of Anabaseine J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1276 - 1284. [Abstract] [Full Text] [PDF]

				L. Chen and M. Sokabe Presynaptic Modulation of Synaptic Transmission by Pregnenolone Sulfate as Studied by Optical Recordings J Neurophysiol, December 1, 2005; 94(6): 4131 - 4144. [Abstract] [Full Text] [PDF]

				W. R. Kem, V. M. Mahnir, L. Prokai, R. L. Papke, X. Cao, S. LeFrancois, K. Wildeboer, K. Prokai-Tatrai, J. Porter-Papke, and F. Soti Hydroxy Metabolites of the Alzheimer's Drug Candidate 3-[(2,4-Dimethoxy)Benzylidene]-Anabaseine Dihydrochloride (GTS-21): Their Molecular Properties, Interactions with Brain Nicotinic Receptors, and Brain Penetration Mol. Pharmacol., January 1, 2004; 65(1): 56 - 67. [Abstract] [Full Text] [PDF]

				S. Shaw, M. Bencherif, and M. B. Marrero Angiotensin II Blocks Nicotine-Mediated Neuroprotection against {beta}-Amyloid (1-42) via Activation of the Tyrosine Phosphatase SHP-1 J. Neurosci., December 3, 2003; 23(35): 11224 - 11228. [Abstract] [Full Text] [PDF]

				P. Dobelis, S. Hutton, Y. Lu, and A. C. Collins GABAergic Systems Modulate Nicotinic Receptor-Mediated Seizures in Mice J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1159 - 1166. [Abstract] [Full Text] [PDF]

				S. Shaw, M. Bencherif, and M. B. Marrero Janus Kinase 2, an Early Target of alpha 7 Nicotinic Acetylcholine Receptor-mediated Neuroprotection against Abeta -(1-42) Amyloid J. Biol. Chem., November 15, 2002; 277(47): 44920 - 44924. [Abstract] [Full Text] [PDF]

				K. T. Dineley, K. A. Bell, D. Bui, and J. D. Sweatt beta -Amyloid Peptide Activates alpha 7 Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes J. Biol. Chem., July 5, 2002; 277(28): 25056 - 25061. [Abstract] [Full Text] [PDF]

				R. L. Papke Enhanced Inhibition of a Mutant Neuronal Nicotinic Acetylcholine Receptor by Agonists: Protection of Function by (E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine (TC-2403) J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 765 - 773. [Abstract] [Full Text] [PDF]

				T. K. Machu, M. E. Hamilton, T. F. Frye, C. L. Shanklin, M. C. Harris, H. Sun, T. E. Tenner Jr., F. S. Soti, and W. R. Kem Benzylidene Analogs of Anabaseine Display Partial Agonist and Antagonist Properties at the Mouse 5-Hydroxytryptamine3A Receptor J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1112 - 1119. [Abstract] [Full Text] [PDF]

				Y. Tizabi, B. Getachew, M. Davila-Garcia, and R. E. Taylor Alcohol preference: association with reduced striatal nicotinic receptors Alcohol Alcohol., July 1, 2001; 36(4): 318 - 322. [Abstract] [Full Text] [PDF]

				M. M. Francis, E. Y. Cheng, G. A. Weiland, and R. E. Oswald Specific Activation of the alpha 7 Nicotinic Acetylcholine Receptor by a Quaternary Analog of Cocaine Mol. Pharmacol., July 1, 2001; 60(1): 71 - 79. [Abstract] [Full Text]

				A. J. Grottick, G. Trube, W. A. Corrigall, J. Huwyler, P. Malherbe, R. Wyler, and G. A. Higgins Evidence That Nicotinic alpha 7 Receptors Are Not Involved in the Hyperlocomotor and Rewarding Effects of Nicotine J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1112 - 1119. [Abstract] [Full Text]

				M. M. Francis, R. W. Vazquez, R. L. Papke, and R. E. Oswald Subtype-Selective Inhibition of Neuronal Nicotinic Acetylcholine Receptors by Cocaine Is Determined by the alpha 4 and beta 4 Subunits Mol. Pharmacol., July 1, 2000; 58(1): 109 - 119. [Abstract] [Full Text]

				Y. Fu, S. G. Matta, and B. M. Sharp Local alpha -Bungarotoxin-Sensitive Nicotinic Receptors Modulate Hippocampal Norepinephrine Release by Systemic Nicotine J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 133 - 139. [Abstract] [Full Text]

				E. M. Meyer, A. Kuryatov, V. Gerzanich, J. Lindstrom, and R. L. Papke Analysis of 3-(4-Hydroxy, 2-Methoxybenzylidene)Anabaseine Selectivity and Activity at Human and Rat Alpha-7 Nicotinic Receptors J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 918 - 925. [Abstract] [Full Text]

				M. Bencherif, J. D. Schmitt, B. S. Bhatti, P. Crooks, W. S. Caldwell, M. E. Lovette, K. Fowler, L. Reeves, and P. M. Lippiello The Heterocyclic Substituted Pyridine Derivative (±)-2-(-3-pyridinyl)-1-Azabicyclo[2.2.2]octane (RJR-2429): A Selective Ligand at Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 886 - 894. [Abstract] [Full Text]

				E. M. Meyer, E. T. Tay, J. A. Zoltewicz, C. Meyers, M. A. King, R. L. Papke, and C. M. De Fiebre Neuroprotective and Memory-Related Actions of Novel Alpha-7 Nicotinic Agents with Different Mixed Agonist/Antagonist Properties J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1026 - 1032. [Abstract] [Full Text]

				K. A. Stauderman, L. S. Mahaffy, M. Akong, G. Veliçelebi, L. E. Chavez-Noriega, J. H. Crona, E. C. Johnson, K. J. Elliott, A. Gillespie, R. T. Reid, et al. Characterization of Human Recombinant Neuronal Nicotinic Acetylcholine Receptor Subunit Combinations alpha 2beta 4, alpha 3beta 4 and alpha 4beta 4 Stably Expressed in HEK293 Cells J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 777 - 789. [Abstract] [Full Text]

				W. R. Kem, V. M. Mahnir, R. L. Papke, and C. J. Lingle Anabaseine Is a Potent Agonist on Muscle and Neuronal Alpha-Bungarotoxin-Sensitive Nicotinic Receptors J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 979 - 992. [Abstract] [Full Text]

				J. P. Sullivan, D. Donnelly-Roberts, C. A. Briggs, D. J. Anderson, M. Gopalakrishnan, I. C. Xue, M. Piattoni-Kaplan, E. Molinari, J. E. Campbell, D. G. Mckenna, et al. ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 235 - 246. [Abstract] [Full Text]

				A. I. Sacaan, R. T. Reid, E. M. Santori, P. Adams, L. D. Correa, L. S. Mahaffy, L. Bleicher, N. D. P. Cosford, K. A. Stauderman, I. A. McDonald, et al. Pharmacological Characterization of SIB-1765F: A Novel Cholinergic Ion Channel Agonist J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 373 - 383. [Abstract] [Full Text]

				O. Delbono, M. Gopalakrishnan, M. Renganathan, L. M. Monteggia, M. L. Messi, and J. P. Sullivan Activation of the Recombinant Human alpha 7 Nicotinic Acetylcholine Receptor Significantly Raises Intracellular Free Calcium J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 428 - 438. [Abstract] [Full Text]

				B. Buisson, M. Gopalakrishnan, S. P. Arneric, J. P. Sullivan, and D. Bertrand Human alpha 4beta 2 Neuronal Nicotinic Acetylcholine Receptor in HEK 293 Cells: A Patch-Clamp Study J. Neurosci., December 15, 1996; 16(24): 7880 - 7891. [Abstract] [Full Text] [PDF]